LX1001
LX1001 is an experimental gene therapy for Alzheimer's disease associated with mutations to the APOE4 gene. The gene therapy is delivered via adeno-associated virus injected into the spinal canal and is intended to increase the expression of APOE2.[1][2][3]
References[edit]
- ^ Ayyubova, Gunel (March 2024). "APOE4 is a Risk Factor and Potential Therapeutic Target for Alzheimer's Disease". CNS & Neurological Disorders Drug Targets. 23 (3): 342–352. doi:10.2174/1871527322666230303114425. PMID 36872358. S2CID 257363252.
- ^ Thomas, Uduak (1 November 2023). "Antibodies Take Center Stage in Alzheimer's: Antibody-based treatments have transformed oncology, and they could do the same for neurodegenerative disorders like Alzheimer's disease". Genetic Engineering & Biotechnology News. 43 (11): 30–32, 34. doi:10.1089/gen.43.11.11. S2CID 265134072.
- ^ Cummings, Jeffrey L.; Osse, Amanda M. Leisgang; Kinney, Jefferson W. (October 2023). "Alzheimer's Disease: Novel Targets and Investigational Drugs for Disease Modification". Drugs. 83 (15): 1387–1408. doi:10.1007/s40265-023-01938-w. PMC 10582128. PMID 37728864.